5-methoxypsoralen has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
5-Methoxypsoralen: A linear furanocoumarin that has phototoxic and anti-inflammatory properties, with effects similar to METHOXSALEN. It is used in PUVA THERAPY for the treatment of PSORIASIS.
5-methoxypsoralen : A 5-methoxyfurocoumarin that is psoralen substituted by a methoxy group at position 5.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Salvador, A | 1 |
| Dall'Acqua, S | 1 |
| Sardo, MS | 1 |
| Caffieri, S | 1 |
| Vedaldi, D | 1 |
| Dall'Acqua, F | 1 |
| Borgatti, M | 1 |
| Zuccato, C | 1 |
| Bianchi, N | 1 |
| Gambari, R | 1 |
1 other study available for 5-methoxypsoralen and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Erythroid induction of chronic myelogenous leukemia K562 cells following treatment with a photoproduct derived from the UV-A irradiation of 5-methoxypsoralen.
Topics: 5-Methoxypsoralen; Antineoplastic Agents; Cell Differentiation; Erythroid Cells; Heterocyclic Compou | 2010 |